Business UpdateJul 14, 2026, 05:27 PM
Biotricity Details Medical Technology Business & Strategy
AI Summary
Biotricity Inc. detailed its medical technology business, focusing on biometric data monitoring solutions for cardiac diagnostics and chronic care management. The company highlighted its FDA-cleared Bioflux and Biocore devices, including the recent launch of the cellular Biocore Pro, and its direct-to-consumer Bioheart monitor. Biotricity is expanding its sales footprint, developing AI-driven solutions, and pursuing an insourcing business model to differentiate itself in the market.
Key Highlights
- Biotricity focuses on biometric data monitoring solutions for diagnostic and post-diagnostic care.
- Key products include FDA-cleared Bioflux COM technology, Biocore ECG/arrhythmia monitor, and Bioheart consumer heart monitor.
- Launched Biocore Pro, a cellular version of Biocore, in late 2024 and expanded sales to 35 states.
- Developing advanced ECG algorithms, Biocore Pro 2.0, and AI-driven predictive monitoring tools with Amazon and Google.
- Targets 34,000 cardiologist offices, 780 hospitals, and 300 IDTFs in the US.
- Utilizes an insourcing business model for COM and Holter markets, with average reimbursement rates of $850 and $200 respectively.
- Plans future expansion into implantable cardiac devices, diabetes, sleep apnea, chronic pain, and fetal monitoring.
Price Impact
More from BTCY